These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
601 related articles for article (PubMed ID: 34419065)
1. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis. Zhao C; Ling X; Xia Y; Yan B; Guan Q Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065 [TBL] [Abstract][Full Text] [Related]
2. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer. Li S; Jiang F; Chen F; Deng Y; Pan X J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205 [TBL] [Abstract][Full Text] [Related]
3. METTL3 Mediated MALAT1 m6A Modification Promotes Proliferation and Metastasis in Osteosarcoma Cells. Zhang Y; Xu Y; Qiu G; Luo Y; Bao Y; Lu J; Wang T; Wang Y Mol Biotechnol; 2024 Dec; 66(12):3538-3548. PubMed ID: 37897586 [TBL] [Abstract][Full Text] [Related]
4. METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma. He F; Ren T; Tang X Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):193-197. PubMed ID: 37605570 [TBL] [Abstract][Full Text] [Related]
5. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway. Ye K; Li L; Wu B; Wang D Genes Genomics; 2022 Nov; 44(11):1311-1322. PubMed ID: 36074324 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of methyltransferase like 3 in epithelial-mesenchymal transition process, invasion, and metastasis in esophageal cancer. Liang X; Zhang Z; Wang L; Zhang S; Ren L; Li S; Xu J; Lv S Bioengineered; 2021 Dec; 12(2):10023-10036. PubMed ID: 34666602 [TBL] [Abstract][Full Text] [Related]
7. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression. Li S; Lu X; Zheng D; Chen W; Li Y; Li F J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010 [TBL] [Abstract][Full Text] [Related]
8. m Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG. Xu LM; Zhang J; Ma Y; Yuan YJ; Yu H; Wang J; Cao XC; Zhu L; Wang P Oncogene; 2022 Mar; 41(12):1742-1751. PubMed ID: 35121826 [TBL] [Abstract][Full Text] [Related]
10. m6A-mediated lncRNA NEAT1 plays an oncogenic role in non-small cell lung cancer by upregulating the HMGA1 expression through binding miR-361-3p. Qi L; Yin Y; Sun M Genes Genomics; 2023 Dec; 45(12):1537-1547. PubMed ID: 37688756 [TBL] [Abstract][Full Text] [Related]
11. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP. Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729 [TBL] [Abstract][Full Text] [Related]
12. METTL3-deficiency m6A-dependently degrades MALAT1 to suppress NLRP3-mediated pyroptotic cell death and inflammation in Mycobacterium tuberculosis (H37Ra strain)-infected mouse macrophages. Han L; Tieliwaerdi N; Li X Tuberculosis (Edinb); 2024 May; 146():102502. PubMed ID: 38458103 [TBL] [Abstract][Full Text] [Related]
13. lncRNA MALAT1/miR‑26a/26b/ST8SIA4 axis mediates cell invasion and migration in breast cancer cell lines. Wang N; Cao S; Wang X; Zhang L; Yuan H; Ma X Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34278507 [TBL] [Abstract][Full Text] [Related]
14. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270 [TBL] [Abstract][Full Text] [Related]
16. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis. Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899 [TBL] [Abstract][Full Text] [Related]
17. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC. Cao Y; Di X; Cong S; Tian C; Wang Y; Jin X; Zhao M; Zhou X; Li R; Wang K Life Sci; 2023 Feb; 315():121359. PubMed ID: 36608868 [TBL] [Abstract][Full Text] [Related]
18. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer. Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397 [TBL] [Abstract][Full Text] [Related]
19. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner. Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135 [TBL] [Abstract][Full Text] [Related]
20. METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelial-mesenchymal transition. Wang Y; Chen Y; Liang J; Jiang M; Zhang T; Wan X; Wu J; Li X; Chen J; Sun J; Hu Y; Huang P; Feng J; Liu T; Sun X J Mol Cell Biol; 2023 Aug; 15(3):. PubMed ID: 36945110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]